Cargando…

Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis

Interferons are widely used platform therapies as disease-modifying treatment of patients with multiple sclerosis. Although interferons are usually safe and well tolerated, they frequently cause dermatological side effects. Here, we present a multiple sclerosis (MS) patient treated with interferon-β...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolb-Mäurer, Annette, Goebeler, Matthias, Mäurer, Mathias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519881/ https://www.ncbi.nlm.nih.gov/pubmed/26147425 http://dx.doi.org/10.3390/ijms160714951

Ejemplares similares

Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis
por: Balak, Deepak MW, et al.
Publicado: (2011)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
por: Bayas, Antonios, et al.
Publicado: (2015)

Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-β-1b: a case report
por: Sahraian, Mohammad Ali, et al.
Publicado: (2013)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
por: Holmøy, Trygve, et al.
Publicado: (2019)

Interferon Beta and Vitamin D Synergize to Induce Immunoregulatory Receptors on Peripheral Blood Monocytes of Multiple Sclerosis Patients
por: Waschbisch, Anne, et al.
Publicado: (2014)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
por: Kolb-Mäurer, Annette, et al.
Publicado: (2019)

Interferon Treatment of Multiple Sclerosis
por: Alajbegovic, Azra, et al.
Publicado: (2012)

Bone marrow sarcoidosis associated with long‐term interferon‐β treatment for multiple sclerosis
por: Teh, Angela, et al.
Publicado: (2016)

Early stage and long term treatment of multiple sclerosis with interferon-β
por: Applebee, Angela, et al.
Publicado: (2009)

Oral contraceptives combined with interferon β in multiple sclerosis
por: Pozzilli, Carlo, et al.
Publicado: (2015)

Endogenous Interferon-β-Inducible Gene Expression and Interferon-β-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2015)

Special Issue “Cutaneous Lymphomas”
por: Wobser, Marion, et al.
Publicado: (2023)

Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature Review
por: Sirbu, Carmen Adella, et al.
Publicado: (2022)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Creeke, Paul I., et al.
Publicado: (2013)

Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review
por: Faghihi, Gita, et al.
Publicado: (2015)

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
por: Krueger, James G., et al.
Publicado: (2016)

Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis
por: Manfredonia, Francesco, et al.
Publicado: (2008)

Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
por: Hegen, Harald, et al.
Publicado: (2016)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis
por: Freedman, Mark S
Publicado: (2014)

Thrombotic microangiopathy associated with interferon-beta treatment in patients with multiple sclerosis
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2018)

Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-β Treatment in Multiple Sclerosis
por: Gandhi, Kaushal S., et al.
Publicado: (2010)

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β
por: De Felice, Bruna, et al.
Publicado: (2014)

Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis
por: Yetkin, Mehmet Fatih, et al.
Publicado: (2016)

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
por: Furber, Kendra L, et al.
Publicado: (2017)

Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers
por: Muñoz, Delicias, et al.
Publicado: (2013)

Mental Health in Multiple Sclerosis Patients without Limitation of Physical Function: The Role of Physical Activity
por: Tallner, Alexander, et al.
Publicado: (2015)

Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus
por: Sprangers, Ben, et al.
Publicado: (2017)

Interferon–β Induces Hepatocyte Growth Factor in Monocytes of Multiple Sclerosis Patients
por: Molnarfi, Nicolas, et al.
Publicado: (2012)

The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events
por: Hehir, Michael K., et al.
Publicado: (2022)

Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
por: Jeannin, S., et al.
Publicado: (2011)

CD10-Positive Cutaneous PEComa: An Extremely Rare Skin Tumour
por: Ueberschaar, Simon, et al.
Publicado: (2020)

Fatigue in Multiple Sclerosis Is Associated With Childhood Adversities
por: Pust, Gesa E. A., et al.
Publicado: (2020)

Ocular adverse events from pharmacological treatment in patients with multiple sclerosis—A systematic review of the literature
por: Muñoz-Ortiz, Juliana, et al.
Publicado: (2021)

Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis
por: Zhornitsky, Simon, et al.
Publicado: (2015)

Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases
por: Etemadifar, Masoud, et al.
Publicado: (2011)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ca0h6q97nnmq402a4tu8s7c8i9